AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study to Evaluate Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Peripheral Neuropathic Pain
- First Posted Date
- 2009-09-14
- Last Posted Date
- 2009-12-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 90
- Registration Number
- NCT00976534
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2009-09-14
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 154
- Registration Number
- NCT00976495
- Locations
- 🇺🇸
Prism Research, St. Paul, Minnesota, United States
🇺🇸Memorial Hospital Of Rhode Island, Pawtucket, Rhode Island, United States
🇳🇱Local Institution, Groningen, Netherlands
Lung Deposition Via Different Inhalation Devices
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2009-09-11
- Last Posted Date
- 2009-12-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT00975754
- Locations
- 🇸🇪
Research Site, Lund, Sweden
Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055
- First Posted Date
- 2009-09-09
- Last Posted Date
- 2011-06-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 19
- Registration Number
- NCT00973076
- Locations
- 🇯🇵
Research Site, Tokyo, Japan
Trial to Evaluate the Efficacy and Safety of Dapagliflozin in Japanese Type 2 Diabetes Mellitus Patients
- First Posted Date
- 2009-09-04
- Last Posted Date
- 2013-10-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 417
- Registration Number
- NCT00972244
- Locations
- 🇯🇵
Research Site, Yamato, Japan
Study to Assess Safety, Tolerability and Pharmacokinetics After Single Dose of AZD2516 to Japanese Healthy Subjects
- First Posted Date
- 2009-09-04
- Last Posted Date
- 2010-03-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00972049
- Locations
- 🇯🇵
Research Site, Fukuoka, Japan
Study of Artery Conditions of 'At-risk' Asian People Not on Lipid-lowering Drugs
- Conditions
- Cardiovascular Disease
- Interventions
- Procedure: Measurement of the Carotid Intima Media thicknessBiological: Blood sample testing for hs-CRP
- First Posted Date
- 2009-09-03
- Last Posted Date
- 2010-09-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2609
- Registration Number
- NCT00970918
- Locations
- 🇻🇳
Research Site, Hanoi, Vietnam
Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2009-09-02
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 291
- Registration Number
- NCT00970268
- Locations
- 🇺🇸
Forest Investigative Site 2029, Rancho Mirage, California, United States
🇺🇸Forets Investigative Site 2064, Riverside, California, United States
🇺🇸Forest Investigative Site 2067, Butte, Montana, United States
AZD2423 Single Ascending Dose Study in Healthy Japanese Subjects
- First Posted Date
- 2009-09-02
- Last Posted Date
- 2010-03-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT00970775
- Locations
- 🇬🇧
Research Site, London, United Kingdom
AZD5985 Single Ascending Dose Study
- First Posted Date
- 2009-08-27
- Last Posted Date
- 2009-11-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 72
- Registration Number
- NCT00967356
- Locations
- 🇸🇪
Research Site, Goteborg, Sweden